Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

IgE/FcεRI-Mediated Antigen Cross-Presentation by Dendritic Cells Enhances Anti-Tumor Immune Responses.

Platzer B, Elpek KG, Cremasco V, Baker K, Stout MM, Schultz C, Dehlink E, Shade KT, Anthony RM, Blumberg RS, Turley SJ, Fiebiger E.

Cell Rep. 2015 Mar 3. pii: S2211-1247(15)00143-6. doi: 10.1016/j.celrep.2015.02.015. [Epub ahead of print]

2.

Mutations in G protein β subunits promote transformation and kinase inhibitor resistance.

Yoda A, Adelmant G, Tamburini J, Chapuy B, Shindoh N, Yoda Y, Weigert O, Kopp N, Wu SC, Kim SS, Liu H, Tivey T, Christie AL, Elpek KG, Card J, Gritsman K, Gotlib J, Deininger MW, Makishima H, Turley SJ, Javidi-Sharifi N, Maciejewski JP, Jaiswal S, Ebert BL, Rodig SJ, Tyner JW, Marto JA, Weinstock DM, Lane AA.

Nat Med. 2015 Jan;21(1):71-5. doi: 10.1038/nm.3751. Epub 2014 Dec 8.

3.

The tumor microenvironment shapes lineage, transcriptional, and functional diversity of infiltrating myeloid cells.

Elpek KG, Cremasco V, Shen H, Harvey CJ, Wucherpfennig KW, Goldstein DR, Monach PA, Turley SJ.

Cancer Immunol Res. 2014 Jul;2(7):655-67. doi: 10.1158/2326-6066.CIR-13-0209. Epub 2014 Mar 31.

4.

Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages.

Gautier EL, Shay T, Miller J, Greter M, Jakubzick C, Ivanov S, Helft J, Chow A, Elpek KG, Gordonov S, Mazloom AR, Ma'ayan A, Chua WJ, Hansen TH, Turley SJ, Merad M, Randolph GJ; Immunological Genome Consortium.

Nat Immunol. 2012 Nov;13(11):1118-28. doi: 10.1038/ni.2419. Epub 2012 Sep 30.

5.

Podoplanin-rich stromal networks induce dendritic cell motility via activation of the C-type lectin receptor CLEC-2.

Acton SE, Astarita JL, Malhotra D, Lukacs-Kornek V, Franz B, Hess PR, Jakus Z, Kuligowski M, Fletcher AL, Elpek KG, Bellemare-Pelletier A, Sceats L, Reynoso ED, Gonzalez SF, Graham DB, Chang J, Peters A, Woodruff M, Kim YA, Swat W, Morita T, Kuchroo V, Carroll MC, Kahn ML, Wucherpfennig KW, Turley SJ.

Immunity. 2012 Aug 24;37(2):276-89. doi: 10.1016/j.immuni.2012.05.022. Epub 2012 Aug 9.

6.

Deciphering the transcriptional network of the dendritic cell lineage.

Miller JC, Brown BD, Shay T, Gautier EL, Jojic V, Cohain A, Pandey G, Leboeuf M, Elpek KG, Helft J, Hashimoto D, Chow A, Price J, Greter M, Bogunovic M, Bellemare-Pelletier A, Frenette PS, Randolph GJ, Turley SJ, Merad M; Immunological Genome Consortium.

Nat Immunol. 2012 Sep;13(9):888-99. doi: 10.1038/ni.2370. Epub 2012 Jul 15.

7.

Transcriptional profiling of stroma from inflamed and resting lymph nodes defines immunological hallmarks.

Malhotra D, Fletcher AL, Astarita J, Lukacs-Kornek V, Tayalia P, Gonzalez SF, Elpek KG, Chang SK, Knoblich K, Hemler ME, Brenner MB, Carroll MC, Mooney DJ, Turley SJ; Immunological Genome Project Consortium.

Nat Immunol. 2012 Apr 1;13(5):499-510. doi: 10.1038/ni.2262.

8.

PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network.

Ying H, Elpek KG, Vinjamoori A, Zimmerman SM, Chu GC, Yan H, Fletcher-Sananikone E, Zhang H, Liu Y, Wang W, Ren X, Zheng H, Kimmelman AC, Paik JH, Lim C, Perry SR, Jiang S, Malinn B, Protopopov A, Colla S, Xiao Y, Hezel AF, Bardeesy N, Turley SJ, Wang YA, Chin L, Thayer SP, DePinho RA.

Cancer Discov. 2011 Jul;1(2):158-69. doi: 10.1158/2159-8290.CD-11-0031. Epub 2011 May 23.

9.

Regulated release of nitric oxide by nonhematopoietic stroma controls expansion of the activated T cell pool in lymph nodes.

Lukacs-Kornek V, Malhotra D, Fletcher AL, Acton SE, Elpek KG, Tayalia P, Collier AR, Turley SJ.

Nat Immunol. 2011 Sep 18;12(11):1096-104. doi: 10.1038/ni.2112.

10.

Lymphoid organ-resident dendritic cells exhibit unique transcriptional fingerprints based on subset and site.

Elpek KG, Bellemare-Pelletier A, Malhotra D, Reynoso ED, Lukacs-Kornek V, DeKruyff RH, Turley SJ.

PLoS One. 2011;6(8):e23921. doi: 10.1371/journal.pone.0023921. Epub 2011 Aug 19.

11.

Mature natural killer cells with phenotypic and functional alterations accumulate upon sustained stimulation with IL-15/IL-15Ralpha complexes.

Elpek KG, Rubinstein MP, Bellemare-Pelletier A, Goldrath AW, Turley SJ.

Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21647-52. doi: 10.1073/pnas.1012128107. Epub 2010 Nov 22.

12.

The stromal and haematopoietic antigen-presenting cells that reside in secondary lymphoid organs.

Turley SJ, Fletcher AL, Elpek KG.

Nat Rev Immunol. 2010 Dec;10(12):813-25. doi: 10.1038/nri2886. Epub 2010 Nov 19. Review.

PMID:
21088682
13.

Tumor cells engineered to codisplay on their surface 4-1BBL and LIGHT costimulatory proteins as a novel vaccine approach for cancer immunotherapy.

Sharma RK, Yolcu ES, Elpek KG, Shirwan H.

Cancer Gene Ther. 2010 Oct;17(10):730-41. doi: 10.1038/cgt.2010.29. Epub 2010 Jun 18.

14.

4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines.

Sharma RK, Schabowsky RH, Srivastava AK, Elpek KG, Madireddi S, Zhao H, Zhong Z, Miller RW, Macleod KJ, Yolcu ES, Shirwan H.

Cancer Res. 2010 May 15;70(10):3945-54. doi: 10.1158/0008-5472.CAN-09-4480. Epub 2010 Apr 20.

15.

A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity.

Schabowsky RH, Elpek KG, Madireddi S, Sharma RK, Yolcu ES, Bandura-Morgan L, Miller R, MacLeod KJ, Mittler RS, Shirwan H.

Vaccine. 2009 Dec 11;28(2):512-22. doi: 10.1016/j.vaccine.2009.09.127. Epub 2009 Oct 29.

16.

Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors.

Sharma RK, Elpek KG, Yolcu ES, Schabowsky RH, Zhao H, Bandura-Morgan L, Shirwan H.

Cancer Res. 2009 May 15;69(10):4319-26. doi: 10.1158/0008-5472.CAN-08-3141. Epub 2009 May 12.

17.

Intestinal tolerance is converted to autoimmune enteritis upon PD-1 ligand blockade.

Reynoso ED, Elpek KG, Francisco L, Bronson R, Bellemare-Pelletier A, Sharpe AH, Freeman GJ, Turley SJ.

J Immunol. 2009 Feb 15;182(4):2102-12. doi: 10.4049/jimmunol.0802769.

18.

Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells.

Epardaud M, Elpek KG, Rubinstein MP, Yonekura AR, Bellemare-Pelletier A, Bronson R, Hamerman JA, Goldrath AW, Turley SJ.

Cancer Res. 2008 Apr 15;68(8):2972-83. doi: 10.1158/0008-5472.CAN-08-0045.

19.

Ex vivo expansion of CD4+CD25+FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling.

Elpek KG, Yolcu ES, Franke DD, Lacelle C, Schabowsky RH, Shirwan H.

J Immunol. 2007 Dec 1;179(11):7295-304.

20.
21.

Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice.

Gomez-Gutierrez JG, Elpek KG, Montes de Oca-Luna R, Shirwan H, Sam Zhou H, McMasters KM.

Cancer Immunol Immunother. 2007 Jul;56(7):997-1007. Epub 2006 Dec 5.

PMID:
17146630
22.

Tolerance to rat heart grafts induced by intrathymic immunomodulation is mediated by indirect recognition primed CD4+CD25+ Treg cells.

Köksoy S, Elpek KG, Yolcu ES, Shirwan H.

Transplantation. 2005 Jun 15;79(11):1492-7.

PMID:
15940037

Supplemental Content

Loading ...
Support Center